Optimal Care Pathways for myelodysplastic syndromes (MDS) patients
- Myelodysplastic syndromes
- Myeloproliferative neoplasms
Tag: Myelodysplastic syndromes
Optimal Care Pathways for myelodysplastic syndromes (MDS) – HCP
- Myelodysplastic syndromes
- Myeloproliferative neoplasms
Navigating a rare blood disease as a mother of five: Fiona’s story
In May 2020, Fiona was diagnosed with Myelodysplastic Syndrome. Also known as MDS, it is a type of blood cancer that affects the production of normal blood cells in the bone marrow. Fiona shares what it was like to be diagnosed with a rare blood disease as a mother of five, wife and nurse, in the midst of the COVID-19 pandemic.
- Myelodysplastic syndromes
Clinical trial for high-risk MDS tests new drug combination
A Phase I investigator-driven clinical trial, which is ready to recruit its first participant, gives Australian patients with high-risk MDS access to two new oral drugs.
- Clinical trials
- Myelodysplastic syndromes
- Research
Don had a stem cell transplant at 70 and says “exercise helped”
Don Hayes had an allogeneic stem cell transplant days before his 71st birthday.
- Myelodysplastic syndromes
- Research
- Treatments and side-effects
Jane’s had three different cancer diagnoses in two years
- Acute myeloid leukaemia
- Myelodysplastic syndromes
- Treatments and side-effects
Expert Series: Prof. John Pimanda – lots of work is needed to improve long-term outcomes for MDS
- Interviews with experts
- Myelodysplastic syndromes
- Treatments and side-effects
Diagnosed with MDS, AML, then MDS again
Tony Wakely’s diagnosis with MDS quickly transformed to AML, which he beat with a transplant. But a year later, he was shocked to find out his MDS had come back.
- Acute myeloid leukaemia
- Myelodysplastic syndromes
International precision medicine clinical trials recruiting
Two new international clinical trials are expected to improve access to new therapies for Australians with MDS as part of the Leukaemia Foundation’s Trials Enabling Program (TEP).
- Clinical trials
- Myelodysplastic syndromes
- Research
PBAC update on new MDS & CMML treatment
The Leukaemia Foundation provided consumer comments to the Pharmaceutical Benefits Advisory Committee (PBAC) in relation to Otsuka Australia Pharmaceutical’s resubmission for decitabine and cedazuridine (Inqovi®) for high-risk MDS and CMML.
- Myelodysplastic syndromes
- Treatments and side-effects
